This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) June 3, 2023
✳️10 tweet #NephJC catch-up ✳️
🌟Let’s recap the RITAZAREM trial - a rematch between Rituximab and Azathioprine as the maintenance agent of choice in relapsed ANCA-associated vasculitis.
🌟Have we witnessed the ultimate triumph of Rituximab? pic.twitter.com/HbFKhe6MKc
Is Rituximab better than azathioprine for maintenance therapy of relapse in ANCA-associated vasculitis? Checkout the RITAZAREM study VA.
